Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2021-03-30 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
109年度應收帳款周轉率
Regulatory Filings Classification · 90% confidence The document is very short (281 characters) and contains financial ratio data (accounts receivable turnover and average collection days) for two fiscal years (108 and 109). There is no indication of a full financial report, management discussion, or detailed analysis. The content resembles a brief financial metric disclosure rather than a comprehensive report. Given the brevity and nature of the data, it is likely a Regulatory Filing (RNS) as a general disclosure or compliance update rather than a full Annual Report, Interim Report, or Earnings Release.
2021-03-30 Chinese
109年第4季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial data specifically related to changes in equity, including items such as common stock capital, capital surplus, legal reserve, special reserve, undistributed earnings, and other comprehensive income components. The data is presented for the current and previous fiscal years, indicating a comprehensive financial statement. The presence of detailed financial tables and accounting items suggests this is part of a formal financial report rather than a brief announcement or summary. The document length is 4555 characters, which is sufficient to contain substantive financial data. There is no indication that this is an announcement of a report or a certification. The content aligns with the characteristics of an Interim / Quarterly Report (IR), as it provides substantive financial data for a period shorter than a full fiscal year (quarter or half-year). Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2021-03-30 Chinese
109年度毛利率
Fund Information / Factsheet Classification · 90% confidence The document contains annual financial data for two years (108年度 and 109年度) including net operating revenue, operating costs, gross profit, and gross profit margin percentages. The data is presented in a tabular format and includes a note about significant changes in gross profit margin. The document length is very short (386 characters), and it appears to be a brief financial summary rather than a full annual report or detailed financial statement. There is no indication that this is an announcement of a report publication or a certification. Given the brief nature and summary format, this fits best as a Fund Information / Factsheet (FS), which is typically a brief summary of key financial facts.
2021-03-30 Chinese
補充公告本公司參與認購子公司杏國新藥(股)公司 109年度第二次以私募方式辦理現金增資發行之普通股新股
Capital/Financing Update Classification · 95% confidence The document is a disclosure announcement from a listed company (杏輝) regarding its participation in a private placement capital increase of its subsidiary 杏國新藥. It details the transaction specifics such as number of shares, price, total amount, relationship between parties, board approval dates, and accounting firm information. The document is short (1938 characters) and focuses on a specific capital transaction event rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes.
2021-03-22 Chinese
本公司董事會決議通過109年度合併財務報告案
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (1734 杏輝) reporting that the board of directors has approved the consolidated financial report for the fiscal year 109 (covering 109/01/01 to 109/12/31). It includes summarized financial data such as revenue, gross profit, operating loss, net loss, total assets, liabilities, and equity. The document is short (905 characters) and appears to be a formal disclosure of the board's resolution to approve the annual consolidated financial report rather than the full annual report itself. There is no detailed financial statement or comprehensive analysis present, only key financial figures and the approval statement. According to the "Menu vs Meal" rule, this is an announcement of the approval of the annual financial report, not the full report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not contain the full report.
2021-03-16 Chinese
本公司擬於參與認購子公司杏國新藥(股)公司109年度第二次以私 募方式辦理現金增資發行之普通股新股
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from a listed company (杏輝) regarding its intention to participate in a private placement capital increase of its subsidiary 杏國新藥. It details the transaction specifics such as the nature of the securities, transaction date, pricing, relationship between parties, board approval, and accounting firm involved. The document is short (2005 characters) and primarily serves as a disclosure of a capital/financing activity rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the capital increase transaction details. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-03-16 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.